Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Accumulated Expenses: 2014-2024

Historic Accumulated Expenses for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $40.6 million.

  • ImmunityBio's Accumulated Expenses rose 0.01% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 0.01%. This contributed to the annual value of $40.6 million for FY2024, which is 4.98% down from last year.
  • Per ImmunityBio's latest filing, its Accumulated Expenses stood at $40.6 million for FY2024, which was down 4.98% from $42.7 million recorded in FY2023.
  • ImmunityBio's 5-year Accumulated Expenses high stood at $51.4 million for FY2021, and its period low was $36.8 million during FY2020.
  • For the 3-year period, ImmunityBio's Accumulated Expenses averaged around $41.7 million, with its median value being $41.8 million (2022).
  • As far as peak fluctuations go, ImmunityBio's Accumulated Expenses spiked by 588.21% in 2020, and later fell by 18.61% in 2022.
  • ImmunityBio's Accumulated Expenses (Yearly) stood at $36.8 million in 2020, then surged by 39.75% to $51.4 million in 2021, then dropped by 18.61% to $41.8 million in 2022, then increased by 2.11% to $42.7 million in 2023, then decreased by 4.98% to $40.6 million in 2024.